Other Information
−Removed: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the quarter ended March 31, 2025, as such terms are defined under Item 408 (a) of Regulation S-K.
−Removed: Additionally, we did not adopt or terminate a Rule 10b5–1 trading arrangement during the quarter ended March 31, 2025.
−Removed: Incorporation by Reference
−Removed: Term Sheet, dated as of January 5, 2025, between the Company and JGS Holdings LLC
−Removed: Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on January 10, 2025
−Removed: Securities Purchase Agreement, dated January 27, 2025, by and among the Company and the purchaser signatories thereto.
−Removed: Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on January 29, 2025
−Removed: Consent and Waiver Agreement, dated January 27, 2025, by and among the Company and the signatories thereto.
−Removed: Exhibit 10.3 to the Company’s Current Report on Form 8-K filed on January 29, 2025
−Removed: Form of Amended and Restated Securities Purchase Agreement, dated as of January 28, 2025, by and among the Company and the Investor.
−Removed: Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on February 3, 2025
−Removed: Form of Second Amended and Restated Securities Purchase Agreement, dated as of February 3, 2025, by and among the Company and the Investor.
−Removed: Exhibit 10.2 to the Company’s Current Report on Form 8-K filed on February 3, 2025
+Added: None of our directors or executive officers adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement during the quarter ended June 30, 2025, as such terms are defined under Item 408 (a) of Regulation S-K.
+Added: Additionally, we did not adopt or terminate a Rule 10b5–1 trading arrangement during the quarter ended June 30, 2025.
Asset Purchase and Contribution Agreement, dated as of May 9, 2025, by and among Hope Therapeutics, Inc.
−Removed: and the signatories thereto.
+Added: and the signatories thereto (incorporated by reference to Exhibit 10.6 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2025.
Membership Interest Purchase and Contribution Agreement, by and among Hope Therapeutics, Inc.
−Removed: and the signatories thereto.
+Added: and the signatories thereto (incorporated by reference to Exhibit 10.7 to the Company’s Quarterly Report on Form 10-Q, filed on May 15, 2025.
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
9 unchanged sentences
Cover Page Interactive Data File (formatted in iXBRL and contained in Exhibit 101)
−Removed: Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulations S-K.
−Removed: The Company will furnish supplementally an unredacted copy of such exhibit to the Securities and Exchange Commission or its staff upon request.
Filed herewith.
4 unchanged sentences
NRX PHARMACEUTICALS, INC.
+Added: August 15, 2025
/s/ Jonathan Javitt
1 unchanged sentence
(Principal Executive Officer)
−Removed: Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
−Removed: NRX PHARMACEUTICALS, INC.
−Removed: /s/ Michael Abrams
−Removed: Chief Financial Officer
−Removed: (Principal Financial Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.